In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
María Espinosa-AlcantudChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-1126-2458 Núria SimaChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-4097-1402 Irene Fernández-DuranChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0003-1289-7276 Anna Marazuela-DuqueChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-6787-8668 Gerard Martínez-CebriánTranscriptional Dynamics in Leukemia Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0002-8626-1353 Anna Guitart-SolanesChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0003-2110-6990 Andrés Gámez-GarcíaChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0003-4927-3678 Paloma Martínez-RedondoChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Laia Bosch-PreseguéChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-8025-2416 Berta N VazquezChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0002-8164-3926 Luis PañosChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0002-9316-2871 Tim ThomasThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.ORCID 0000-0002-7623-8344 Marian A Martinez-BalbásDepartment of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona 08028, Spain.ORCID 0000-0003-0173-0964 Anne K VossThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.ORCID 0000-0002-3853-9381 Marcus KrügerDepartment of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, D-61231 Bad Nauheim, Germany.ORCID 0000-0002-5846-6941 Lourdes SerranoDepartment of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, 145 Bevier Road, Piscataway, NJ 08854, USA.ORCID 0000-0001-7641-5796 Mireia OlivellaBioinformatics and Medical Statistics Group, Faculty of Science, Technology and Engineering, University of Vic-Central University of Catalonia, 08500 Vic Catalunya, Spain.ORCID 0000-0002-6035-3399 Sergi CuarteroTranscriptional Dynamics in Leukemia Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Carolina de la TorreProteomics Unit, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.ORCID 0000-0001-9363-291X Alejandro VaqueroChromatin Biology Laboratory, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-8735-4156 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Mitosis entry is tightly regulated by a complex network of mechanisms involving epigenetic modifications, signaling pathways, transcriptional control, and structural changes. Although substantial progress has been made in understanding these processes individually, the mechanisms integrating chromatin dynamics with mitotic regulators are still not fully understood. Here, we identify a functional antagonism between the deacetylase SIRT2 and the acetyltransferase MOF in the G
Indexed as
Histone AcetyltransferasesMitosisSirtuin 2AcetylationAdenosine TriphosphatasesCell Cycle ProteinsChromatinDNA-Binding ProteinsForkhead Box Protein M1HistonesHumansMultiprotein ComplexesPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsAdenosine TriphosphatasesCell Cycle ProteinsChromatincondensin complexesDNA-Binding ProteinsForkhead Box Protein M1FOXM1 protein, humanHistone AcetyltransferasesHistonesKAT8 protein, humanMultiprotein ComplexesPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsSIRT2 protein, humanSirtuin 2
Identifiers
PMID42319919
PMCPMC13281814
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390